Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial

被引：0
|
作者：
Billings, Liana K.
Doshi, Ankur
Gouet, Didier
Oviedo, Alejandra
Rodbard, Helena W.
Tentolouris, Nikolaos
Gron, Randi
Halladin, Natalie
Jodar, Esteban
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
136-OR
引用
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [31] A comparison of prandial premixed (ILPS/lispro) vs basal bolus (glargine/lispro) insulin therapy in obese patients with type 2 diabetes (T2D)
    Ahmann, Andrew
    Jiang, Honghua
    Martin, Sherry A.
    DIABETES, 2008, 57 : A564 - A564
  • [32] Efficacy and Safety of Liraglutide vs. Placebo When Added to Basal Insulin Analogs in Patients with Type 2 Diabetes (LIRA-ADD2BASAL)
    Ahmann, Andrew J.
    Rodbard, Helena W.
    Rosenstock, Julio
    Lahtela, Jorma
    De Loredo, Luis
    Tornoe, Karen
    Boopalan, Anand
    Nauck, Michael A.
    DIABETES, 2014, 63 : A87 - A87
  • [33] Optimising basal-bolus therapy in type 2 diabetes: a randomised, controlled trial comparing bolus insulin delivery using an insulin patch vs an insulin pen
    Ramtoola, S.
    Aroda, V. R.
    Bailey, T. S.
    Brazg, R. L.
    Dreon, D. M.
    Frias, J. P.
    Klonoff, D. C.
    Kruger, D. F.
    Levy, B. L.
    Peyrot, M.
    Rosenstock, J.
    Serusclat, P.
    Weinstock, R. S.
    Zraicks, V.
    Bergenstal, R. M.
    DIABETOLOGIA, 2018, 61 : S397 - S397
  • [34] Insulin Degludec/Liraglutide (IDegLira) Is Efficacious and Safe in Patients with Type 2 Diabetes (T2D) with Normal, Mild, or Moderate Renal Impairment: Analyses from Phase 3 Trials
    Aroda, Vanita R.
    Bode, Bruce W.
    Davidson, Jaime
    Rodbard, Helena W.
    Andersen, Andreas
    Kaas, Anne
    Vilsboll, Tina
    DIABETES, 2017, 66 : A286 - A286
  • [35] Safety and efficacy of insulin aspart vs. regular human insulin in basal/bolus therapy for patients with gestational diabetes
    Jovanovic, L
    Howard, C
    Pettitt, D
    Zisser, H
    Ospina, P
    DIABETES, 2005, 54 : A675 - A675
  • [36] Efficacy and Safety of IDegLira (Combination of Insulin Degludec plus Liraglutide), in Insulin-Naive Patients with T2D Uncontrolled on GLP-1 Receptor Agonist (GLP-1RA) Therapy
    Linjawi, Sultan
    Bode, Bruce W.
    Chaykin, Louis B.
    Courreges, Jean-Pierre
    Handelsman, Yehuda
    Lehmann, Lucine
    Mishra, Abhishek
    Simpson, Richard W.
    DIABETES, 2015, 64 : A255 - A255
  • [37] LONG-TERM COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN AS INTENSIFICATION THERAPIES FOR PEOPLE WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN IN SPAIN: PROJECTIONS BASED ON THE DUAL VII TRIAL
    Ampudia, F. J.
    Mezquita, P.
    de Arellano, Ramirez A.
    Basse, A.
    Hunt, B.
    VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [38] COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN INTENSIFICATION REGIMENS IN PATIENTS WITH TYPE 2 DIABETES IN SLOVAK SETTING
    Psota, M.
    Racekova, N.
    Psenkova, M.
    Vandebrouck, T.
    Ramirez de Arellano, A.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [39] Proportion and characteristics of patients with type 2 diabetes initiating basal insulin therapy with a basal-bolus regimen in China
    Zhang, Puhong
    Zhang, Heng
    Zhu, Dongshan
    Li, Xian
    Ji, Jiachao
    Zhao, Fang
    Lu, Juming
    Jia, Weiping
    Ji, Linong
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
  • [40] Efficacy, Patient-Reported Outcomes (PRO), and Safety of Insulin Degludec U200 vs. Insulin Glargine in Patients with Type 2 Diabetes (T2D) Requiring High-Dose Insulin
    Warren, Mark
    Chaykin, Louis B.
    Jabbour, Serge
    Sheikh-Ali, Mae
    Hansen, Charlotte T.
    Rasmussen, Soren
    Norwood, Paul
    DIABETES, 2015, 64 : A266 - A267
12345